Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Executive Summary
Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said
You may also be interested in...
Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik
Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik
Sensipar Is $8.10 Per 30 Mg; “Fair Price” For “Major Advance,” Amgen Says
Amgen's Sensipar (cinacalcet) will cost $8.10 per 30 mg tablet, Amgen says